Logo - springer
Slogan - springer

Biomedical Sciences - Cancer Research | Resistance to Proteasome Inhibitors in Cancer - Molecular Mechanisms and Strategies to Overcome

Resistance to Proteasome Inhibitors in Cancer

Molecular Mechanisms and Strategies to Overcome Resistance

Dou, Q. Ping (Ed.)

2014, XI, 390 p. 55 illus., 51 illus. in color.

Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$159.00

(net) price for USA

ISBN 978-3-319-06752-0

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$209.00

(net) price for USA

ISBN 978-3-319-06751-3

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

  • Reveals latest discoveries related to the molecular mechanisms of proteasome inhibitor resistance
  • Discusses proteasome inhibitor resistance in multiple contexts, including multiple myeloma, leukemia, mantle cell lymphoma, melanoma and other cancers
  • Explores multiple, cutting-edge strategies to overcome resistance

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.​

Content Level » Research

Keywords » 20S proteasome inhibitors - bortezomib - carfizomib - leukemia - multiple myeloma - ubiquitin-proteasome pathway

Related subjects » Cancer Research - Medical Microbiology - Molecular Medicine - Pharmacology & Toxicology

Table of contents / Preface / Sample pages 

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Cancer Research.